RE: director buying-token gesture16 May 2018 20:10
Naz11, you make a good point to be fair, and we often see this on AIM, ive seen this theory on many of my holdings. However it is far from a sinking ship. I would find it hard to see how you would just bin T when your phase I and II trials were superb, invest so much money, sign contracts with commercial manufactures to then walk away. You could say many drug companies fail at phase III, but this was catastrophic as in no better than giving patients a smartie...simply not right. They would also be monitoring Japan trials now in depth, so we have that. We also have Caleb which again looks very promising and that’s only to start with. This isn’t a one trick pony. Yes we have to ride the storm, and yes, we can spin good or bad here anyway that suits our agenda but there are facts for all to see, and ultimately that’s what we all make our investment choices on. It’s AIM the roulette of the stock market. But this is massively oversold stemmed by panic and blinkered view of the company being a one time, one trick company, which clearly they aren’t. High risk but high reward here. Would I put my house on it? No. Would I take a gamble? Yes. And that’s what it is right now, but the rewards could be colossal